Med Discovery and DRAXIMAGE Establish Research Collaboration
Med Discovery and DRAXIMAGE, the radiopharmaceutical division of DRAXIS Health Inc. announced that they have established a research collaboration agreement to explore the combination of Med Discovery's targeted protein therapeutics with DRAXIMAGE's radiopharmaceutical expertise in the therapeutic and diagnostics field.
Med Discovery's lead proteins are themselves potential therapeutic agents for prostate cancer and a variety of other cancers. This collaboration provides initially for the radiolabeling of certain Med Discovery's proteins by DRAXIMAGE to assess the enhancement of their therapeutic action and their capability to detect microtumors. The proteins will be produced at Med Discovery in Switzerland and radiolabeled by DRAXIMAGE in Canada.
The data for these proteins from this collaboration will yield information that is essential for commencing clinical studies. This is a prerequisite for their development as potential treatments for cancers where there are currently few satisfactory therapeutic alternatives.
Other news from the department business & finance
